RxDoctor Payments Data

Benjamin Smolar, MD

Neurology · Monroeville, PANPI 1104913714

Payments from drug & device makers

$2,358in general payments, 2019–2025

Across 36 payments — averaging $65.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Products Limited$2K
  • Biogen$150
  • AbbVie$137
  • EMD Serono, Inc.$81
  • Novartis$56
  • Supernus Pharmaceuticals, Inc.$50
  • plus $384 from 13 others

What the payments were for

  • Consulting fees$16619%
  • Food & beverage$61872%
  • Education$739%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,358 in reported general payments places this provider in the 55th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$117,998
Medicare patients
530
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Teriflunomide22$175,602
AubagioTeriflunomide18$165,526
TecfideraDimethyl Fumarate16$145,405
Aimovig AutoinjectorErenumab-Aooe98$77,876
CopaxoneGlatiramer Acetate12$68,196
Glatiramer Acetate19$61,682
Dimethyl Fumarate25$50,509
Emgality PenGalcanezumab-Gnlm37$38,649
Dalfampridine ErDalfampridine50$35,974
QuliptaAtogepant15$29,108
Nurtec OdtRimegepant Sulfate25$24,073
Ajovy AutoinjectorFremanezumab-Vfrm20$21,967
UbrelvyUbrogepant16$17,110
KeppraLevetiracetam15$17,051
Gabapentin794$16,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$48$165,52618 claims
BiogenTecfidera$150$145,40516 claims
AbbVieQulipta, Ubrelvy$137$46,21831 claims
UCB, Inc.Neupro, Briviact$18$18,05425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →